A2 Biotherapeutics develops Tmod™, a precision-targeting T cell therapy platform that distinguishes solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach addresses the challenge of effective treatment for solid tumors while minimizing damage to healthy tissue.

Abatatx offers a managed WordPress hosting service that automates domain verification, DNS configuration, and account provisioning to prevent common setup errors. The platform provides guided onboarding, real‑time support, and monitoring alerts, enabling small to medium businesses and individual site owners to launch and maintain WordPress sites with minimal downtime and technical effort.

The startup develops immunomodulatory therapeutics that target autoimmunity and cancer by utilizing proprietary transcription data analysis to identify key immune system compartments. This approach enables healthcare professionals to tailor treatment plans for more effective patient outcomes.

Abivax is developing obefazimod, an orally administered small molecule that enhances the expression of miR-124 to stabilize immune responses in patients with chronic inflammatory diseases. This approach aims to restore homeostatic levels of cytokines and chemokines, addressing the dysregulated inflammation seen in conditions like ulcerative colitis and rheumatoid arthritis.

ACELYRIN is a late-stage clinical biopharma company focused on the development of therapies targeting unmet medical needs in immunology, specifically through the advancement of izokibep and lonigutamab for conditions like non-infectious non-anterior uveitis and thyroid eye disease. By accelerating the clinical trials and commercialization processes, ACELYRIN aims to deliver transformative treatments that improve patient outcomes and quality of life.

Alamar Biosciences develops NULISA™ technology, which enables the detection of protein biomarkers from a single liquid biopsy sample with attomolar sensitivity and a dynamic range of up to 12 logs. This technology addresses the challenge of early disease diagnosis by providing researchers with a high-throughput platform for profiling clinically relevant biomarkers across various diseases, including cancer and neurodegenerative disorders.

Alpha9 Theranostics develops peptide-based radiopharmaceuticals for the targeted treatment of solid and hematologic malignancies. Their technology aims to improve therapeutic precision and efficacy, addressing the limitations of conventional cancer therapies.

This company develops a minimally invasive surgical device that uses photodynamic therapy to treat aggressive brain tumors. Their device delivers light to cancer cells exposed to a photosensitizer, offering patients a less invasive alternative to traditional brain surgery.

Arcellx develops cell therapies utilizing its proprietary D-Domain technology and ddCAR platform to enhance the efficacy of immune cell treatments for cancer. The company targets relapsed or refractory multiple myeloma, aiming to provide patients with durable responses through its innovative CART-ddBCMA therapy.

Basecamp Bio develops cell and gene therapies using proprietary technologies such as gene editing, RNA engineering, and viral delivery systems to create effective treatments for various diseases. The company addresses the need for efficient manufacturing and development processes in the regenerative medicine sector, enabling faster access to life-saving therapies.

BE Therapeutics is engineering precursor tissue that mimics embryonic brain tissue to replace damaged neocortical and spinal cord tissue, facilitating normal maturation and integration post-transplantation. This technology aims to restore lost functions in individuals affected by stroke, trauma, neurodegeneration, and aging, addressing the current lack of effective treatments for central nervous system damage.

CARGO Therapeutics is developing tri-specific CAR T-cell therapies designed to target and eliminate B-cell lymphoma cells effectively. This approach aims to provide patients with potentially curative treatment options that traditional therapies may not achieve.

Chinook Therapeutics develops targeted therapeutics that focus on addressing significant disease burdens, particularly in kidney diseases. By utilizing advanced biological research and technology, the company aims to enhance patient outcomes and extend life expectancy.

The startup develops a healthcare platform that utilizes clinical intelligence and decision support tools to enhance patient care quality and operational efficiency. By integrating remote patient monitoring, the platform enables healthcare organizations to make informed decisions within clinical workflows, ultimately improving patient outcomes.

Delfi Diagnostics utilizes the DELFI method, which employs advanced machine learning and next-generation sequencing to analyze cell-free DNA fragments from non-invasive blood samples for early cancer detection. This approach enhances the identification of previously unrecognized cancer-associated DNA fragments, addressing the limitations of existing liquid biopsy methods that rely solely on known mutations.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.

The startup develops immunotherapy technologies that utilize tumor-specific antigens derived from endogenous retroviral DNA sequences to enhance cancer treatment efficacy. This approach enables hospitals to accurately assess tumor specificity and immunogenic potential, improving cancer monitoring and management.

Develops first-in-class covalent protein therapeutics using a proprietary synthetic biology platform that incorporates unnatural amino acids to create irreversibly binding "War-Lock" biologics. This approach improves target modulation, reduces off-target effects, and enables sustained therapeutic efficacy with minimal systemic exposure, addressing limitations of traditional protein drugs in treating cancer and other serious diseases.

Exo Therapeutics utilizes its ExoSight™ platform to identify and develop small molecule inhibitors targeting exosites on enzymes involved in oncology and inflammation. This approach aims to enhance the modulation of enzyme activity, addressing the challenge of drugging previously inaccessible targets.

Eyebiotech is a clinical-stage biotechnology company developing therapies that target the Wnt signaling pathway to treat retinal diseases, addressing the limitations of existing treatments that often fail to improve vision or provide long-term solutions. Their lead asset, Restoret, aims to protect and restore vision for patients suffering from conditions like age-related macular degeneration and diabetic macular edema.

Fluent Biosciences offers PIPseq™, a technology that enables single-cell RNA sequencing without complex microfluidic instrumentation, allowing for the rapid and sensitive analysis of individual cells. This approach addresses the challenges of high ambient RNA background and sequencing bias, providing researchers with a cost-effective and scalable solution for diverse applications in cancer, immunology, and neuroscience.

This company offers mobile diagnostic labs that can be rapidly deployed to any healthcare setting. Their system performs a wide range of tests on-site, delivering results in under 30 minutes, while more complex tests are handled by a central lab, improving patient care and reducing healthcare resource utilization.

HilleVax is developing novel vaccines targeting norovirus, which is responsible for over 90% of epidemic non-bacterial gastroenteritis outbreaks and leads to approximately 200,000 deaths annually. The company's focus on vaccine commercialization aims to mitigate the significant global economic burden of norovirus, estimated at $60.3 billion each year.

ImmunOs Therapeutics develops bispecific antibody immunotherapies that direct a patient’s immune system to target cancer cells and inflammatory disease antigens. Their lead candidate, IOS‑1002, combines engineered binding domains and an optimized Fc region to enhance specificity, potency, and half‑life, and is currently in Phase 1 trials, including combination studies with checkpoint inhibitors. The platform aims to provide pharmaceutical partners and clinicians with next‑generation, combination‑ready treatments for solid tumors and rheumatic diseases.